Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ... [Yahoo! Finance]
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update